FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
The US Food and Drug Administration has granted approval for OPDIVO QVANTIG, which contains nivolumab and hyaluronidase. This subcutaneous formulation is indicated for adult patients and pediatric patients 12 years and older who weigh 30 kg or greater. The approved indications include renal cell carcinoma, melanoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, and gastric cancer. The medication may be used as monotherapy or in combination with other agents per specific indications.
The approval document does not report specific adverse events, serious adverse events, discontinuation rates, or tolerability data. No primary or secondary outcome measures, absolute numbers, p-values, or confidence intervals are provided in this regulatory filing. The document explicitly states that causality is not established from this specific approval document.
Key limitations include the restriction that OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma, unresectable or metastatic melanoma, metastatic NSCLC, unresectable or metastatic MSI-H or dMMR CRC, unresectable or metastatic HCC, or unresectable advanced or metastatic ESCC. This document serves as a regulatory review rather than a clinical trial report.
The primary practice relevance is that OPDIVO QVANTIG provides a subcutaneous formulation option for nivolumab-based therapy in the specified cancer indications. Clinicians must interpret this information as a regulatory authorization and not as evidence of clinical efficacy or safety outcomes derived from patient data.
＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)
Nivolumab is a programmed death receptor-1 (PD-1)-blocking antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Hyaluronidase is an endoglycosidase that degrades hyaluronan, thereby increasing tissue permeability and facilitating the subcutaneous absorption of nivolumab.
Opdivo Qvantig is indicated for: - Renal Cell Carcinoma (RCC): Adult patients with intermediate or poor risk advanced RCC as first-line treatment following combination treatment with intravenous nivolumab and ipilimumab; adult patients with advanced RCC as first-line treatment in combination with cabozantinib; adult patients with advanced RCC who have received prior anti-angiogenic therapy. - Melanoma: Adult and pediatric (12 years and older, ≥30 kg) patients with unresectable or metastatic melanoma; following combination treatment with intravenous nivolumab and ipilimumab; adjuvant treatment of completely resected Stage IIB, IIC, III, or IV melanoma. - Non-Small Cell Lung Cancer (NSCLC): Adult patients with resectable NSCLC (tumors ≥4 cm or node positive) in the neoadjuvant setting in combination with platinum-doublet chemotherapy; neoadjuvant treatment followed by adjuvant monotherapy after surgery for tumors ≥4 cm or node positive without EGFR mutations or ALK rearrangements; metastatic NSCLC with progression on or after platinum-based chemotherapy (patients with EGFR or ALK aberrations should have progressed on FDA-approved therapy). - Squamous Cell Carcinoma of the Head and Neck (SCCHN): Adult patients with recurrent or metastatic SCCHN with disease progression on or after platinum-based therapy. - Urothelial Carcinoma (UC): Adjuvant treatment of adults at high risk of recurrence after radical resection; first-line treatment in combination with cisplatin and gemcitabine for unresectable or metastatic UC; locally advanced or metastatic UC with progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant/adjuvant platinum. - Colorectal Cancer (CRC): Adult and pediatric (12 years and older, ≥30 kg) patients with unresectable or metastatic MSI-H or dMMR CRC following combination treatment with intravenous nivolumab and ipilimumab; MSI-H or dMMR metastatic CRC that has progressed after fluoropyrimidine, oxaliplatin, and irinotecan. - Hepatocellular Carcinoma (HCC): Adult patients with unresectable or metastatic HCC as first-line treatment following intravenous nivolumab and ipilimumab; previously treated with sorafenib following intravenous nivolumab and ipilimumab. - Esophageal Cancer: Adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease after neoadjuvant chemoradiotherapy; first-line treatment of unresectable advanced or metastatic ESCC with PD-L1 ≥1 in combination with fluoropyrimidine- and platinum-containing chemotherapy; unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy. - Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma: Adult patients with advanced or metastatic disease with PD-L1 ≥1 in combination with fluoropyrimidine- and platinum-containing chemotherapy.
Not reported in label.
Not reported in label.
Not reported in label.
Opdivo Qvantig provides a subcutaneous formulation of nivolumab, offering an alternative to intravenous administration for multiple approved indications. It is not indicated for use in combination with ipilimumab. The specific place in therapy varies by indication, including first-line treatment in combination with other agents (e.g., cabozantinib for RCC, chemotherapy for NSCLC, UC, ESCC, gastric cancer) or as monotherapy following prior intravenous nivolumab plus ipilimumab.
More on Colorectal Cancer
View Original Abstract ↓
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
New cancer therapies double response rates for tough lymphoma
Related in Oncology
From Other Specialties
